



SPRING 2019 PULMONARY UPDATES

Which Patients with IPF Should be on Antifibrotics? The Value of Shared Decision Making

Mary Beth Scholand, MD

One of the very interesting dilemmas that most clinicians face these days with the availability of antifibrotics in IPF is who should be offered these and should every patient be offered these and or be on an antibiotic therapy, really focusing on who is the appropriate candidate for antibiotic therapy and who should be making that decision, more importantly is it the patient? Is it the provider? And I think the consensus is a shared decision that should be made between the provider and the patient related to antibiotic therapy.